AI Article Synopsis

  • The opioid crisis has been worsened by increased opioid dosing in chronic pain patients, with limited psychological interventions available for reducing these doses.
  • Mindfulness-Oriented Recovery Enhancement (MORE) has shown promise in helping chronic pain patients by improving self-regulation and reducing opioid use, as evidenced by studies showing a 32% decrease in opioid doses among those who participated in MORE compared to a support group.
  • Analysis found that improvements in heart rate variability during mindfulness practices were linked to the success of MORE in reducing opioid use, suggesting that mindfulness can enhance self-control over medication use in patients with chronic pain.

Article Abstract

The current opioid crisis was fueled by escalation of opioid dosing among patients with chronic pain. Yet, there are few evidence-based psychological interventions for opioid dose reduction among chronic pain patients treated with long-term opioid analgesics. Mindfulness-Oriented Recovery Enhancement (MORE), which was designed to target mechanisms underpinning chronic pain and opioid misuse, has shown promising results in 2 randomized clinical trials (RCTs) and could facilitate opioid sparing and tapering by bolstering self-regulation. Here we tested this hypothesis with secondary analyses of data from a Stage 2 RCT. Chronic pain patients (N = 95) on long-term opioid therapy were randomized to 8 weeks of MORE or a support group (SG) control delivered in primary care. Opioid dose was assessed with the Timeline Followback through 3-month follow-up. Heart rate variability (HRV) during mindfulness meditation was quantified as an indicator of self-regulatory capacity. Participants in MORE evidenced a greater decrease in opioid dosing (a 32% decrease) by follow-up than did the SG, F(2, 129.77) = 5.35, p = .006, d = 1.07. MORE was associated with a significantly greater increase in HRV during meditation than was the SG. Meditation-induced change in HRV partially mediated the effect of MORE on opioid dose reduction (p = .034). MORE may boost self-regulatory strength via mindfulness and thereby facilitate self-control over opioid use, leading to opioid dose reduction in people with chronic pain. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490853PMC
http://dx.doi.org/10.1037/amp0000638DOI Listing

Publication Analysis

Top Keywords

opioid dose
20
chronic pain
20
opioid
13
dose reduction
12
mindfulness-oriented recovery
8
recovery enhancement
8
primary care
8
opioid dosing
8
pain patients
8
long-term opioid
8

Similar Publications

Mechanisms of Cancer-Induced Bone Pain.

J Pain Res

January 2025

Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.

Bone is a common site of advanced cancer metastasis, second only to the lungs and liver. Cancer-induced bone pain (CIBP) is a persistent and intense pain that is caused by a combination of inflammatory and neuropathic factors. As CIBP progresses, the degree of pain intensifies.

View Article and Find Full Text PDF

Refractory cancer pain affects 10-20% of patients with advanced malignancies and is not adequately controlled by opioids. The intrathecal therapy is an effective interventional procedure for referral, but the implanted infusion pumps are costly and the refilling requires technical expertise. Hypophysectomy, in its three stages-surgical, chemical, and radiosurgical-has emerged as an alternative for managing this pain.

View Article and Find Full Text PDF

Phytochemical profile of Taxus globosa Schltdl. and its anxiolytic, antinociceptive, and toxicological evaluation in mice.

J Ethnopharmacol

January 2025

Posgrado en Botánica, Colegio Postgraduados Campus Montecillo Km. 36.5 Carretera México-Texcoco C.P. Montecillo, 56264, Texcoco Estado de México, México. Electronic address:

Ethnopharmacological Relevance: Taxus globosa Schltdl. (Taxaceae) is commonly named "Tejo mexicano". It's a Mexican plant known in folk medicine as a remedy for pain such as stomachache and headache, arthritis, gout, and other inflammatory conditions.

View Article and Find Full Text PDF

Pharmacological Characterization of the Novel Selective Kappa Opioid Receptor Agonists 10-Iodo-Akuammicine and 10-Bromo-Akuammicine in Mice.

Neuropharmacology

January 2025

Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Electronic address:

Akuammicine (AKC), an indole alkaloid, is a kappa opioid receptor (KOR) full agonist with a moderate affinity. 10-Iodo-akuammicine (I-AKC) and 10-Bromo-akuammicine (Br-AKC) showed higher affinities for the KOR with K values of 2.4 and 5.

View Article and Find Full Text PDF

Virtual reality for reduction of intraprocedural pharmacological sedation and analgesia in adult patients: A systematic review and meta-analysis.

Anaesth Crit Care Pain Med

January 2025

Department of Anesthesiology and Pain Medicine, Maisonneuve-Rosemont Hospital, Montréal, QC, Canada; Université de Montréal, Montréal, QC, Canada; Maisonneuve-Rosemont Hospital Research Center, Montreal, QC, Canada.

Background: Pharmacological sedation and analgesia are used to alleviate discomfort during awake medical procedures but can cause adverse effects like apnea and hypoxemia, increasing the need for airway management and prolonging recovery. Virtual reality (VR) has emerged as a non-pharmacological intervention to reduce the need for procedural sedatives and analgesics.

Methods: A systematic review and meta-analysis were conducted, assessing the impact of VR immersion on intraprocedural sedation and analgesia usage in adults (≥ 18 years).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!